Insights

Why Novavax Stock Is Soaring Today

What happened
Shares of Novavax (NASDAQ: NVAX) were soaring 12.9% as of 11:24 a.m. ET on Monday. The gain continues the momentum that started on Friday after the Food and Drug Administration (FDA) announced plans to convene an advisory committee to review the Emergency Use Authorization (EUA) filing for Novavax’s COVID-19 vaccine.
Also, investors could be more optimistic about the near-term demand for COVID vaccines in general. Dr. Deborah Birx, the former White House Coronavirus Response Task Force coordinator, warned in an interview with CBS on Sunday that the southern U.S. could experience a summer surge of coronavirus cases.
So what
Some investors appear to be jumping back onto the Novavax bandwagon after the vaccine stock plunged more than 80% below its all-time high set last year. The meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) scheduled for June 7 certainly appears to be a hopeful sign that Novavax could at long last win EUA for its COVID vaccine, NVX-CoV2373.
Sure, the advisory committee must first deliberate. The FDA then has to make its decision on the authorization of NVX-CoV2373. But the likelihood of a thumbs-up seems to be greater than ever, as evidenced by the resurgence in Novavax’s share price.
Dr. Birx’s prediction of a surge in COVID cases probably isn’t nearly as significant of a factor in Novavax’s gains today. But it is possible that another coronavirus wave could bolster the prospects that the U.S. government could promote Novavax’s protein sub-unit vaccine as an alternative for Americans who have been hesitant to receive messenger RNA vaccines.
Image source: Getty Images.

Now what
Novavax continues to work with the FDA in its EUA review process for NVX-CoV2373. It seems likely that the agency will quickly make a decision after the advisory committee meets based on the precedent set with other COVID vaccines.
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

Shares of Novavax (NASDAQ: NVAX) were soaring 12.9% as of 11:24 a.m. ET on Monday. The gain continues the momentum that started on Friday after the Food and Drug Administration (FDA) announced plans to convene an advisory committee to review the Emergency Use Authorization (EUA) filing for Novavax’s COVID-19 vaccine.

Also, investors could be more optimistic about the near-term demand for COVID vaccines in general. Dr. Deborah Birx, the former White House Coronavirus Response Task Force coordinator, warned in an interview with CBS on Sunday that the southern U.S. could experience a summer surge of coronavirus cases.

So what

Some investors appear to be jumping back onto the Novavax bandwagon after the vaccine stock plunged more than 80% below its all-time high set last year. The meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) scheduled for June 7 certainly appears to be a hopeful sign that Novavax could at long last win EUA for its COVID vaccine, NVX-CoV2373.

Sure, the advisory committee must first deliberate. The FDA then has to make its decision on the authorization of NVX-CoV2373. But the likelihood of a thumbs-up seems to be greater than ever, as evidenced by the resurgence in Novavax’s share price.

Dr. Birx’s prediction of a surge in COVID cases probably isn’t nearly as significant of a factor in Novavax’s gains today. But it is possible that another coronavirus wave could bolster the prospects that the U.S. government could promote Novavax’s protein sub-unit vaccine as an alternative for Americans who have been hesitant to receive messenger RNA vaccines.

Image source: Getty Images.

Now what

Novavax continues to work with the FDA in its EUA review process for NVX-CoV2373. It seems likely that the agency will quickly make a decision after the advisory committee meets based on the precedent set with other COVID vaccines.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!